Posts

Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect

Chief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."

Psychedelic Business Spotlight: December 3

This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy TrialShutterstock.com

Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial

Chief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.

Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce

,
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways' novel drug formulation COMP360.
Psychedelic Business Spotlight: November 5

Psychedelic Business Spotlight: November 5

This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
Why We're Excited About Compass Pathways New Clinical Trial Treating PTSD With PsilocybinShutterstock.com

Why We’re Excited About Compass Pathways’ New Clinical Trial Treating PTSD with Psilocybin

,
Compass Pathways (Nasdaq: CMPS) has announced the launch of a brand new psychedelic clinical trial, using psilocybin (the active ingredient in magic mushrooms) to treat PTSD, and there are multiple reasons to be excited about it. The Phase-2…
Why Psychedelic Stocks Have Crashed in the Last 3 Months

Why Psychedelic Stocks Have Crashed in the Last 3 Months

Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.